Healthcare | May 08, 2026
Vijaya Diagnostic Q4FY26 revenue jumps 27%, EBITDA margin expands to 43.5%
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
